Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · Real-Time Price · USD
0.4450
+0.0110 (2.53%)
At close: Aug 13, 2025, 4:00 PM
0.4520
+0.0070 (1.57%)
Pre-market: Aug 14, 2025, 8:29 AM EDT
Clearside Biomedical Stock Forecast
CLSD's stock price has decreased by -58.41% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for Clearside Biomedical stock ranges from a low of $3.00 to a high of $5.00. The average analyst price target of $4.33 forecasts a 873.03% increase in the stock price over the next year.
Price Target: $4.33 (+873.03%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Clearside Biomedical stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $5 | Strong Buy → Hold | Downgrades | $5 | +1,023.60% | Jul 18, 2025 |
| Needham | Needham | Strong Buy → Hold Downgrades $3 | Strong Buy → Hold | Downgrades | $3 | +574.16% | Jul 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $5 | Strong Buy | Maintains | $6 → $5 | +1,023.60% | May 23, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $5 | Buy | Reiterates | $5 | +1,023.60% | May 16, 2025 |
Financial Forecast
Revenue This Year
2.97M
from 1.66M
Increased by 78.37%
Revenue Next Year
3.50M
from 2.97M
Increased by 17.79%
EPS This Year
-0.42
from -0.47
EPS Next Year
-0.62
from -0.42
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.7M | 21.3M | 34.9M | ||
| Avg | 3.0M | 3.5M | 14.8M | ||
| Low | 2.3M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 120.9% | 617.8% | 899.5% | ||
| Avg | 78.4% | 17.8% | 323.9% | ||
| Low | 35.5% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.19 | -0.21 | -0.24 | ||
| Avg | -0.42 | -0.62 | -0.51 | ||
| Low | -0.62 | -1.27 | -0.81 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.